Stockreport

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Vivos Therapeutics, Inc.  (VVOS) 
PDF Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call tod [Read more]